This six-year study, which is lead by McMaster University professors Dr. Hertzel Gerstein and Dr. Salim Yusuf of the Population Health Research Institute, is determining whether insulin glargine and/or omega 3 fatty acids can reduce cardiovascular events in 12,578 people with elevated blood sugar levels from around the world.</blockquote>


Oh wait:

The ORIGIN (Outcome Reduction with an Initial Glargine Intervention) trial is sponsored by Sanofi-Aventis which manufactures insulin glargine.</blockquote>

But then:

To maintain a high-quality and unbiased study, researchers and the manufacturer of insulin glargine do not (and will continue to not) have access to data summarizing outcomes by treatment group until the study is over.</blockquote>